HAS1 and melanoma: Our data show for the first time the biphasic pattern of hyaluronan metabolism in cutaneous melanocytic tumors revealing an increased hyaluronan synthesis in premalignant lesions followed by reduced hyaluronan content in malignant melanoma as a consequence of decreased HAS expression and increased amount of degradative HYAL2.